Neurizon Therapeutics Limited has released a press release.
Expanded Site Recruitment for Phase II MPL Dog Cancer Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Presentation - Pitt Street Research Life Sciences Conference
- Progress in Recruitment for Phase II Trial in Dogs
- AGM Presentation
- Epichem new CEO and Board additions
- Appendix 3B & s708 Notice
Later from Neurizon Therapeutics
- Epichem client gives notice to end contract in February 2020
- Epichem Awarded One-Year Contract Extension from DNDi
- PharmAust Receives $700k R&D Tax Incentive Refund
- Brisbane Animal Hospital Joins Phase II Dog Cancer Trial
- PharmAust to Evaluate Monepantel on COVID-19
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics